Hero Background


Discover, design, and deliver the right drug for the right patient

Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.

We partner with scientists and researchers to accelerate the drug development process

  • 95%

    of the top 20 pharma oncology companies partner with Tempus

  • 200+

    biopharma partnerships

image description

Data Collaborations

  • ~6M

    de-identified research records to power scientific discovery to improve patient outcomes

  • 900K+

    records with matched clinical data linked with genomic information

  • 200K+

    records with whole transcriptome profiles

image description


  • 9

    NGS tests for clinical trial and research sequencing

  • 6.5K+

    oncologists rely on Tempus as their precision medicine partner

image description

Clinical Trial Solutions

  • ~10

    business days for just-in-time trial activation

  • 90+

    health systems representing 500+ sites

  • 30K+

    patients have been identified for potential enrollment into clinical trials in our network

image description
Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.

Jorge DiMartino, Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio

Learn more about our partnership with Kronos

Featured Resources


    Reduce time to launch with Tempus and multimodal data

    How AstraZeneca simplified its approach to TROPION-Lung01 and drove down time to launch.

    Read more

    Make quicker decisions by simulating and contextualizing data with Tempus

    Mirati leverages Tempus data to revise its KRAS strategy and refine its patient selection approach

    Read more

    Enhance your clinical development process with Tempus’ CDx platform

    Learn how A2 Biotherapeutics is making progress on a breakthrough cell therapy using HLA-LOH (human leukocyte antigen-loss of heterozygosity) as a biomarker, using Tempus’ comprehensive immunotherapy platform.

    Read more

    Activate trials faster with the TIME program

    Sermonix was able to accelerate timelines for first patient in and enrollment by working with Tempus

    Read more

    Make critical investment decisions using Tempus’ vast tumor organoid repository

    A large Biopharma collaborator used Tempus’ patient-derived organoids to unlock a critical investment decision

    Read more

    De-risk investment and increase the Probability of Technical Success (PTS) with Tempus

    Learn how AstraZeneca integrated Tempus data and tools across their Oncology R&D governance process.

    Read more

    Introducing Tempus Next: Care Pathway Intelligence Solution

    Chris Scotto DiVetta, SVP of Applications at Tempus AI introduces Tempus Next, an AI enabled care pathway platform that helps providers accelerate the adoption of evidence based care.

    Watch now

    Identifying patients with Valvular Heart Disease: A partnership between a specialty designated cardiac center and Tempus

    Learn how the deployment of Tempus Next, an AI-enabled clinical care pathway solution, at a specialty designated cardiac and heart valve center helped enable guideline directed care for patients with structural heart disease.

    Read more

    Closing the biomarker testing gap for early stage NSCLC patients with Tempus Next

    Learn how Tempus Next was deployed at TriHealth Cancer and Blood Institute in Cincinnati, Ohio to surface and close gaps in biomarker testing for NSCLC patients.

    Read more

Tempus empowers you to make smarter, faster, and more efficient decisions

Get customized solutions for your needs.